Journal of pancreatology最新文献

筛选
英文 中文
Reappraisal of the Parenchyma-Sparing Resections for Pancreatic Neuroendocrine Tumors: A Chinese High-volume Center Experience 重新评估胰腺神经内分泌肿瘤的肾实质切除术:中国高容量中心的经验
Journal of pancreatology Pub Date : 2024-06-18 DOI: 10.1097/jp9.0000000000000184
Haoqi Zhang, Chunlu Tan, Xubao Liu, Xing Wang
{"title":"Reappraisal of the Parenchyma-Sparing Resections for Pancreatic Neuroendocrine Tumors: A Chinese High-volume Center Experience","authors":"Haoqi Zhang, Chunlu Tan, Xubao Liu, Xing Wang","doi":"10.1097/jp9.0000000000000184","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000184","url":null,"abstract":"\u0000 \u0000 Parenchyma-sparing resections (PSRs) are increasingly used for small pancreatic neuroendocrine neoplasms (PNENs) to preserve the function of the gland. However, the data are extremely limited due to the rarity of this tumor.\u0000 \u0000 \u0000 \u0000 This study sought to describe the indications, operative technique, short and long-term outcomes of PSRs for PNENs, with a focus on postoperative pancreatic fistula (POPF) and oncologic outcomes.\u0000 \u0000 \u0000 \u0000 From 2008 to 2018, data collected retrospectively from 113 PNENs that underwent PSRs (113/421, 27%) were reviewed. A comparison was conducted of PSRs of PNENs without (group1, n=101) or with pancreatic transection (group 2, n=12).\u0000 \u0000 \u0000 \u0000 Of the 113 patients, the most common indication for PSRs was insulinoma (80%), followed by NF-PNEN (20%). The majority of lesions were WHO G1 grade (80/113, 71%). The mean maximum diameter of the tumors was 19 mm. Patients who underwent PSRs had a low rate of severe postoperative morbidity (7/113, 6%). Pancreatic endocrine and exocrine insufficiency occurred in only 1% and 7% of patients respectively. And there was no evidence of tumor recurrence after PSRs detected during follow-up. Age was identified as the only independent positive risk factor of POPF in group 1. Patients in group 2 had significantly higher rates of POPF (p=0.002), overall morbidity (p=0.002), severe morbidity (p=0.026) and readmission (p=0.004).\u0000 \u0000 \u0000 \u0000 PSRs of PNENs appear to be feasible and safe, preserving the endocrine and exocrine function of the gland with no increased risk of recurrence or metastasis. In contrast, PSRs involving transection of the pancreas should be performed more cautiously.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"32 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141334779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase angle is an indicator of GLIM-diagnosed malnutrition in patients undergoing major pancreatic and biliary surgery: a cross-sectional study 相位角是胰腺和胆道大手术患者 GLIM 诊断营养不良的指标:一项横断面研究
Journal of pancreatology Pub Date : 2024-06-04 DOI: 10.1097/jp9.0000000000000185
Lijuan Wang, Pengxue Li, Yifu Hu, Bo Cheng, Lei Li, Lili Ding, Jinghai Song, Junmin Wei, Jingyong Xu
{"title":"Phase angle is an indicator of GLIM-diagnosed malnutrition in patients undergoing major pancreatic and biliary surgery: a cross-sectional study","authors":"Lijuan Wang, Pengxue Li, Yifu Hu, Bo Cheng, Lei Li, Lili Ding, Jinghai Song, Junmin Wei, Jingyong Xu","doi":"10.1097/jp9.0000000000000185","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000185","url":null,"abstract":"\u0000 \u0000 The aim of this study is to elucidate the correlation between phase angle and malnutrition, and to determine the malnutrition cut-off points based on phase angle in patients undergoing major pancreatic and biliary surgery.\u0000 \u0000 \u0000 \u0000 This is a cross-sectional study analyzing the prospective database of the Department of Hepatopancreatobiliary Surgery at Beijing Hospital, China, from December 2020 to September 2023. Basal data, diet surveys, anthropometry, and body composition were recorded. Phase angle was measured with the InBody 720. The GLIM criteria were used to diagnose malnutrition. Subgroup analyses were conducted by stratifying age and pancreatic cancer.\u0000 \u0000 \u0000 \u0000 A total of 185 consecutive cases were included, with a mean age of 63.66;±11.96 years. 63.8% (118/185) of the participants were aged 60 years or older, and 43.8% (81/185) were diagnosed with pancreatic cancer. The prevalence of malnutrition was 62.2% among all subjects, 67.8% among the elderly, and 69.1% among pancreatic cancer patients. Phase angle was significantly lower in the malnourished group than in the normal group. Positive correlations were found between phase angle and BMI, ASMI, FFMI, fat-free mass, total energy intake, grip strength, calf circumference, 6-meter timed walk speed, total protein, albumin, and prealbumin. Among all the subjects, participants with a lower phase angle were significantly more likely to suffer from malnutrition than their control group, with a 1.611 times higher risk (95% CI 1.013-2.562, P=0.044). The cut-off points of the phase angle for determining malnutrition were 4.82 in men (sensitivity 0.744, specificity 0.571, area under the curve 0.667, 95% CI 0.567-0.766, P = 0.003), and 4.54 in women (sensitivity 0.750, specificity 0.711, area under the curve 0.757, 95% CI 0.644-0.869, P < 0.001). In the subgroup analyses of elderly and pancreatic cancer patients, we obtained consistent results with statistical significance and identified corresponding cut-off points.\u0000 \u0000 \u0000 \u0000 The present study suggests that the phase angle could be a valid, useful, and simple indicator of malnutrition in patients undergoing major pancreatic and biliary surgery.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"93 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141268029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consensus on the Clinical Diagnosis and Treatment of Grade 3 Pancreatic Neuroendocrine Tumors 3 级胰腺神经内分泌肿瘤的临床诊断和治疗共识
Journal of pancreatology Pub Date : 2024-04-25 DOI: 10.1097/jp9.0000000000000183
Jie Chen, Wenming Wu, Chunmei Bai, Yihebali Chi, Li Huo, Liming Jiang, Yuan Ji, Jie Luo, Jie Li, Jingnan Li, W. Lou, Chenghao Shao, Lin Shen, Feng Wang, Yu Wang, Ling Xue, Jin Xu, Chunhui Yuan, Xianjun Yu, Xiaoyu Yin, Hong Zhao, Xiongzeng Zhu, Yupei Zhao
{"title":"Consensus on the Clinical Diagnosis and Treatment of Grade 3 Pancreatic Neuroendocrine Tumors","authors":"Jie Chen, Wenming Wu, Chunmei Bai, Yihebali Chi, Li Huo, Liming Jiang, Yuan Ji, Jie Luo, Jie Li, Jingnan Li, W. Lou, Chenghao Shao, Lin Shen, Feng Wang, Yu Wang, Ling Xue, Jin Xu, Chunhui Yuan, Xianjun Yu, Xiaoyu Yin, Hong Zhao, Xiongzeng Zhu, Yupei Zhao","doi":"10.1097/jp9.0000000000000183","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000183","url":null,"abstract":"The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly-differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index and cell differentiation. As a new category, G3 pNETs remains a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"14 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140656167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis 重症急性胰腺炎患者服用乌司他丁联合奥曲肽与单用奥曲肽的对比:荟萃分析
Journal of pancreatology Pub Date : 2024-04-17 DOI: 10.1097/jp9.0000000000000181
Siyao Zeng, Yue Li, Lianghe Wen, Yunlong Li, Zhipeng Yao, Yang Cao, Ming Li, Hongliang Wang, Junbo Zheng
{"title":"Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis","authors":"Siyao Zeng, Yue Li, Lianghe Wen, Yunlong Li, Zhipeng Yao, Yang Cao, Ming Li, Hongliang Wang, Junbo Zheng","doi":"10.1097/jp9.0000000000000181","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000181","url":null,"abstract":"\u0000 \u0000 For severe acute pancreatitis (SAP), the combination of urinastatin and octreotide (OCT) is increasingly used. This meta-analysis assesses whether the combination therapy of urinastatin and OCT is more effective than using sole OCT in treating SAP.\u0000 \u0000 \u0000 \u0000 After searching 12 databases in English and Chinese as well as two clinical trial centers up to October 7, 2023, we compared the combination of urinastatin and OCT with sole OCT in treating SAP. Statistical measures utilized include risk ratios (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI).\u0000 \u0000 \u0000 \u0000 We summarized 145 studies from 145 hospitals in 26 provinces, municipalities, and autonomous regions of China, including 13,605 patients. It was found that for SAP, using urinastatin combined with OCT compared to using sole OCT can improve the total effective rate (I\u0000 \u0000 2\u0000 = 0%; RR: 1.22; 95% CI: 1.19-1.24; P < 0.01), reduce mortality rate (I\u0000 \u0000 2\u0000 = 0%; RR: 0.21; 95% CI: 0.09-0.46; P < 0.01), and reduce the overall incidence rate of complications (I\u0000 \u0000 2\u0000 = 0%; RR: 0.28; 95% CI: 0.23-0.34; P < 0.01). In addition, combination therapy reduced in-hospital length of stay, abdominal pain relief time, time for blood and urine amylase to return to normal, inflammatory markers, and improved oxidative stress indicators, immune function indicators, and hemorheology indicators.\u0000 \u0000 \u0000 \u0000 Low-quality evidence suggests that for SAP, the combined use of urinastatin and OCT may be associated with better improvement in patients' symptoms, signs, CT imaging manifestations, and laboratory indicators such as inflammatory markers, oxidative stress markers, immune function indicators, and hemorheological indicators compared to using OCT alone. Additionally, the combination therapy compared to monotherapy may also be associated with lower mortality, a reduced incidence rate of complications, and a shorter in-hospital length of stay. Future research calls for multicenter, high-quality, well-designed studies to validate our findings.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"156 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated analysis of single-cell and bulk RNA sequencing to construct a CD8 + T cell-related immune gene signature in pancreatic cancer 综合分析单细胞和大量 RNA 测序,构建胰腺癌 CD8 + T 细胞相关免疫基因特征
Journal of pancreatology Pub Date : 2024-04-16 DOI: 10.1097/jp9.0000000000000180
Yuzhi Liu, Fei Xu, Anyi Jiang, Jie Ding, Chungao Li, Ming Quan
{"title":"Integrated analysis of single-cell and bulk RNA sequencing to construct a CD8 + T cell-related immune gene signature in pancreatic cancer","authors":"Yuzhi Liu, Fei Xu, Anyi Jiang, Jie Ding, Chungao Li, Ming Quan","doi":"10.1097/jp9.0000000000000180","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000180","url":null,"abstract":"\u0000 \u0000 Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor that responds poorly to immunotherapy. The pivotal influence of CD8 + T-cell infiltration on immunotherapy has been documented in various solid tumors. However, the specific contribution of CD8 + T cell-associated immune genes (TIGs) to the tumor immune microenvironment remains unclear.\u0000 \u0000 \u0000 \u0000 We obtained CD8 + T cell-related immune genes from the INNATE and IMMPORT databases. Univariate analysis and lasso regression analysis were utilized to screen hub TIGs and develop a prognostic signature, the TIGs score. This score was used to evaluate prognosis, immunocyte infiltration, cancer-associated signaling pathways, and the potential responsiveness of immunotherapy. The transcriptomic data and single-cell data from the GSE183795 and GE212966 datasets are employed to validate the reliability of the findings.\u0000 \u0000 \u0000 \u0000 Our findings suggest that patients with low TIGs scores have stronger immune effector functions and immune checkpoint activation, resulting in a more favorable response to PD-L1 inhibitors. TIGs scores were significantly correlated with various molecular characteristics and clinical outcomes, such as tumor mutation burden, multiple tumor-associated pathways, and chemotherapeutic drug sensitivity. PSME2 was identified as a potential prognostic biomarker for predicting survival in patients with PDAC.\u0000 \u0000 \u0000 \u0000 This study elucidates the intricate regulatory mechanisms of TIGs within the tumor immune microenvironment of pancreatic cancer. Our findings strongly suggest that the TIGs score is a robust prognostic marker for prognosis and immunotherapy responsiveness. Additionally, targeting PSME2 may offer a novel avenue for enhancing the effectiveness of immunotherapy in pancreatic cancer.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"352 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140698050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Insights for the Evolving Intervention Strategy for non-Mild Acute Pancreatitis: 35-Year Experience in a Chinese Tertiary Center 非轻度急性胰腺炎干预策略演变的现实世界启示:一家中国三级医疗中心的 35 年经验
Journal of pancreatology Pub Date : 2024-04-12 DOI: 10.1097/jp9.0000000000000179
Xiaxiao Yan, Jingya Zhou, Jian Cao, Qiang Xu, Xianlin Han, Duan Wang, Shengyu Zhang, Dong Wu
{"title":"Real-world Insights for the Evolving Intervention Strategy for non-Mild Acute Pancreatitis: 35-Year Experience in a Chinese Tertiary Center","authors":"Xiaxiao Yan, Jingya Zhou, Jian Cao, Qiang Xu, Xianlin Han, Duan Wang, Shengyu Zhang, Dong Wu","doi":"10.1097/jp9.0000000000000179","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000179","url":null,"abstract":"\u0000 \u0000 With the accumulation of experience and evidence, guidelines for invasive intervention for acute pancreatitis (AP) have continuously evolved, followed in Peking Union Medical College Hospital (PUMCH). We aimed to review AP case series to help understand the impact of guideline evolution on the management and prognosis of AP in real-world practice.\u0000 \u0000 \u0000 \u0000 This was a single-center study of AP patients who had received invasive interventions from 1988 to 2022. Patient demographics, baseline severity, imaging findings, and the indication, timing, and specific modalities of invasive interventions were collected. The composite primary endpoint was death during hospitalization or major complications after intervention. Other endpoints included pancreatic fistula, incision infection, number of interventions, length of intensive care stay, length of hospitalization, and total medical cost.\u0000 \u0000 \u0000 \u0000 A total of 195 patients were included. The most common indication for invasive intervention was suspected infection, followed by persistent symptoms. The step-up and delayed strategies reduced the incidence of major complications or death. Over 35 years, the number of patients requiring surgery has gradually declined, and more patients need only minimally invasive procedures for remission. The incidence of the primary outcome decreased as well as the duration of hospitalization.\u0000 \u0000 \u0000 \u0000 The management of AP patients at PUMCH in the last 35 years has undergone therapeutic guideline changes that support the efficacy and safety of the deferred step-up strategy in real-world practice.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"5 41","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Acute Pancreatitis in End-Stage Renal Disease: Unraveling etiologies, clinical presentations, management strategies, and complications: a narrative review 了解终末期肾病急性胰腺炎:解读病因、临床表现、管理策略和并发症:叙述性综述
Journal of pancreatology Pub Date : 2024-04-12 DOI: 10.1097/jp9.0000000000000182
Chloe Lahoud, Zeina Morcos, Ryan Njeim, Mark Tawfik, Taimur Aslam, Suzanne El-Sayegh
{"title":"Understanding Acute Pancreatitis in End-Stage Renal Disease: Unraveling etiologies, clinical presentations, management strategies, and complications: a narrative review","authors":"Chloe Lahoud, Zeina Morcos, Ryan Njeim, Mark Tawfik, Taimur Aslam, Suzanne El-Sayegh","doi":"10.1097/jp9.0000000000000182","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000182","url":null,"abstract":"Acute pancreatitis (AP) is a common disease with defined diagnostic criteria, radiological findings, and management guidelines. Patients with end-stage renal disease (ESRD) are at an increased risk of developing AP. The diagnosis of AP in ESRD is challenging, and the clinical presentation may mimic other pathologies. Moreover, the impact of AP on the overall morbidity and mortality in ESRD patients warrants a tailored therapeutic approach.\u0000 We conducted a literature search for published manuscripts on AP and ESRD up to November 2023 in several databases such as Google Scholar and PubMed, and employed the following search terms: “acute pancreatitis”, “pancreatitis”, “end-stage renal disease”, “hemodialysis”, “peritoneal dialysis”, “diagnostic criteria”, “etiology”, “presentation”, “management”, “complication”, “prognosis”, “mortality”. Qualitative and quantitative data were both extracted.\u0000 This manuscript reviews current evidence-based literature about the etiology and clinical presentation of AP in ESRD. It sheds the light on the current clinical studies that reflect beneficial management strategies as well as complications of AP in ESRD. Patients with ESRD are more likely to develop AP and subsequently severe pancreatitis with high mortality rates compared to the general population. The etiology of AP in ESRD is multifactorial and management is focused on pain control, early nutritional support and most importantly maintaining a fluid balance. While existing research has shed light on certain aspects of AP in ESRD, additional literature focused on this topic is required to foster a deeper and broader understanding of AP in ESRD.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"14 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140711912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute pancreatitis: pathogenesis and emerging therapies. 急性胰腺炎:发病机制和新兴疗法。
Journal of pancreatology Pub Date : 2024-03-01 Epub Date: 2024-01-02 DOI: 10.1097/JP9.0000000000000168
Saif Zaman, Fred Gorelick
{"title":"Acute pancreatitis: pathogenesis and emerging therapies.","authors":"Saif Zaman, Fred Gorelick","doi":"10.1097/JP9.0000000000000168","DOIUrl":"10.1097/JP9.0000000000000168","url":null,"abstract":"<p><p>Acute pancreatitis is a severe inflammatory disorder with limited treatment options. Improved understanding of disease mechanisms has led to new and potential therapies. Here we summarize what we view as some of the most promising new therapies for treating acute pancreatitis, emphasizing the rationale of specific treatments based on disease mechanisms. Targeted pharmacologic interventions are highlighted. We explore potential treatment benefits and risks concerning reducing acute injury, minimizing complications, and improving long-term outcomes. Mechanisms associated with acute pancreatitis initiation, perpetuation, and reconstitution are highlighted, along with potential therapeutic targets and how these relate to new treatments.</p>","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"7 1","pages":"10-20"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different response of two primary neoplastic lesions to neoadjuvant therapy: a case report 两种原发性肿瘤病变对新辅助治疗的不同反应:病例报告
Journal of pancreatology Pub Date : 2024-02-22 DOI: 10.1097/jp9.0000000000000174
C. Pang, Zhiyao Fan, Hanxiang Zhan
{"title":"Different response of two primary neoplastic lesions to neoadjuvant therapy: a case report","authors":"C. Pang, Zhiyao Fan, Hanxiang Zhan","doi":"10.1097/jp9.0000000000000174","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000174","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor, which is mostly solitary in the pancreas. Surgery-based comprehensive treatment with adjuvant chemotherapy is the currently advanced treatment modality, neoadjuvant chemotherapy has achieved satisfactory results, however, due to the high heterogeneity of PDAC, its sensitivity to chemotherapy is also different. A 66-year-old man presented with discomfort in the upper abdomen and Computed Tomography (CT) scans revealed two tumor lesions in the head and tail of the pancreas, respectively. Endoscopic ultrasonoraphy guided fine needle aspiration (EUS-FNA) was performed to clarify the pathology and the patient was recommended to undergo neoadjuvant therapy. Through five courses of neoadjuvant chemotherapy, the two tumors showed different treatment effects, and after evaluation, total pancreatectomy and splenectomy were provided to patients.We report a case of the one patient presenting with two pancreatic cancer lesions, who demonstrated different therapeutic responses after receiving neoadjuvant chemotherapy due to the heterogeneity of PDAC.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"9 s2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer 免疫相关特征确定 IL1R2 是胰腺癌的免疫学和预后生物标志物
Journal of pancreatology Pub Date : 2024-02-22 DOI: 10.1097/jp9.0000000000000175
Chengcheng Wang, Yuan Chen, Xinpeng Yin, Ruiyuan Xu, Rexiati Ruze, Jianlu Song, Chenglin Hu, Yupei Zhao
{"title":"Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer","authors":"Chengcheng Wang, Yuan Chen, Xinpeng Yin, Ruiyuan Xu, Rexiati Ruze, Jianlu Song, Chenglin Hu, Yupei Zhao","doi":"10.1097/jp9.0000000000000175","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000175","url":null,"abstract":"\u0000 \u0000 Pancreatic cancer is one of the most aggressive malignancies, a robust prognostic signature and novel biomarkers are urgently needed for accurate stratification of the patients and optimization of clinical decision-making.\u0000 \u0000 \u0000 \u0000 A list of bioinformatic analysis were applied in public dataset to construct an immune-related signature. Furthermore, the most pivotal gene in the signature was identified. The potential mechanism of the core gene function was revealed through GSEA, CIBERSORT, ESTIMATE, immunophenoscore algorithm, single cell analysis and functional experiment.\u0000 \u0000 \u0000 \u0000 An immune-related prognostic signature and associated nomogram were constructed and validated. Among the genes constituting the signature, IL1R2 was identified as the gene occupying the most paramount position in the risk signature. Meanwhile, Knockdown of IL1R2 significantly inhibited the proliferation, invasion and migration ability of pancreatic cancer cells. Additionally, high IL1R2 expression was associated with reduced CD8+ T cell infiltration in pancreatic cancer microenvironment, which may be due to high PD-L1 expression in cancer cells. Finally, the IPS algorithm proved that patients with high IL1R2 expression possessed a higher tumor mutation burden and a higher probability of benefiting from immunotherapy.\u0000 \u0000 \u0000 \u0000 In conclusion, our study constructed an efficient immune-related prognostic signature and identified the key role of IL1R2 in the development of pancreatic cancer, as well as its potential to serve as a biomarker for immunotherapy efficacy prediction for pancreatic cancer.\u0000","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"33 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140441490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信